Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6436650

N=C(N)Nc1ncc(Cl)c2ccc(C(=O)NCC(=O)O)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
KLK1 P06870 1/20 0.39
KLK5 Q9Y337 1/20 0.39
PLAU P00749 2/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
KDM4E B2RXH2 3/20 0.36
MAPT P10636 1/20 0.36
HIF1A Q16665 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
EGLN1 Q9GZT9 4/20 0.36
EGLN3 Q9H6Z9 2/20 0.36
DGAT1 O75907 1/20 0.35
LMNA P02545 1/20 0.35
F2 P00734 1/20 0.35
MAPK1 P28482 1/20 0.34
KCNQ3 O43525 1/20 0.34
KCNQ2 O43526 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7447057 0.93 CA1 (0.46) CA1CA2PLAUITGB3ITGA2B
SCHEMBL6436657 0.86 KDM4E (0.38) KDM4EMAPTLMNAKCNQ3KCNQ2
Trifluoroacetic Acid SCHEMBL6434979 0.84 CA2 (0.46) CA1CA2ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6434983 0.84 CA2 (0.46) CA1CA2ITGB3ITGA2B
SCHEMBL6436503 0.83 CA1 (0.48) CA1CA2PLAUITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6434379 0.83 CA2 (0.46) CA1CA2KLK1KLK5DGAT1
SCHEMBL6437624 0.82 PTPRC (0.43) CA1CA2KDM4EMAPTLMNA
Trifluoroacetic Acid SCHEMBL6434344 0.82 KLK1 (0.38) KLK1KLK5PLAUKDM4EHTR5A
Trifluoroacetic Acid SCHEMBL6434862 0.82 CTSA (0.42) ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6437718 0.81 CA2 (0.45) CA1CA2PLAUEGLN1DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CA1 3943/4885CA2 3285/4885KLK1 613/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CA1 3943/4885CA2 3285/4885KLK1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.